ENDOVIA HEALTH SCIENCES INC
EDVANYSE AMERICANTrading Snapshot
- Day Range
- $0.18 – $0.18
- 52-Week Range
- $0.16 – $13.40
- Volume
- $2.96B
- Avg Volume
- $2.43B
- Shares Outstanding
- 6.4M
- Next Earnings
- Dec 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $314,392
- Last Q Revenue
- $80,707
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own EDVA
- ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ENDOVIA HEALTH SCIENCES INC
EDVA
StockOtter · stockotter.spaceAbout ENDOVIA HEALTH SCIENCES INC
Endovia Health Sciences is a diversified cannabinoid-based health sciences platform. The company's strategy focuses on three main areas: commercializing differentiated cannabinoid-based pharmaceutical products internationally, advancing cannabinoid-based human and veterinary therapeutics through U.S. regulatory pathways, and developing consumer wellness and beverage products. This marks a strategic transformation from its prior operations as a beverage company.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
Endovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines
Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
Endovia Health Sciences believes the federal government's affirmative support for Schedule III represents a significant evolution in U.S. cannabinoid poli
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
FORT LAUDERDALE, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) ("Endovia Health" or the "Company") announced that
Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday
FORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its com